Cytek Biosciences, Inc. (CTKB) stock
Close on Nov 12, 2026Market cap $717.51MP/E –Yield –
Cytek Biosciences, Inc. grew revenue 5.5% to $207.65M over the twelve months to Sep 30, 2026. Free cash flow was -$13.48M. At the latest close the market valued the company at $717.51M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $717.51M
- P/E ratio
- –
- Price to sales
- 3.46
- Price to book
- 2.23
- Dividend yield
- –
- Free cash flow yield
- -1.88%
Fundamentals
- Revenue
- $207.65M
- Net income
- -$81.20M
- EPS, diluted
- -$0.63
- Free cash flow
- -$13.48M
- Book value per share
- $2.47
- Diluted shares
- 130M
Trading
- Next earnings
- Feb 25, 2027 (estimated, during market hours)
- Previous close
- $5.76
- Open
- $5.68
- Day's range
- $5.45 – $5.69
- Volume
- 789,061
- Average volume (20 days)
- 1,249,478
- Index membership
- Russell 2000 (since Sep 2021), Russell 3000 (since Aug 2021)
- Beta (5 years)
- 1.09
- 52-week range
- $3.31 – $6.33
- RSI (14 days)
- 46.6
- Volatility (1 year)
- 55.7%
- Relative volume
- 0.70×
- WACC
- 10.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CTKB | S&P 500 | Difference | CTKB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.0% | -2.7% | +6.7 pts | ||
| 3 months | +15.5% | -1.7% | +17.2 pts | ||
| Year to date | +9.3% | +11.9% | −2.6 pts | ||
| 1 year | +14.8% | +12.0% | +2.8 pts | ||
| 3 years | +12.7% | +78.2% | −65.5 pts | +4.1% | +21.2% |
| 5 years | -76.6% | +73.2% | −149.9 pts | -25.2% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cytek Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About Cytek Biosciences
Laboratory Analytical Instruments
Cytek develops and sells cell analysis instruments, reagents, software, and services for biomedical research and clinical diagnostics. Its core products include full spectrum flow cytometers and cell sorters under the Aurora and Northern Lights brands, as well as conventional and imaging systems under the Amnis and Guava lines. The company also provides automated sample loaders, antibody cocktail preparation systems, reagent kits, and analysis software such as SpectroFlo and Cytek Cloud. Customers include pharmaceutical and biotechnology companies, contract research organizations, academic and governmental research institutions, and clinical laboratories.
Company profile, executives and historyCytek Biosciences stock: common questions
What is Cytek Biosciences's stock price?
CTKB closed at $5.52 on Nov 12, 2026, down 4.17% on the day. Over the past 52 weeks it traded between $3.31 and $6.33.
What is Cytek Biosciences's market cap?
Cytek Biosciences was worth $717.51M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CTKB's P/E ratio?
Cytek Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.63), so it has no meaningful P/E ratio.
How much revenue does Cytek Biosciences make?
Cytek Biosciences reported revenue of $207.65M for the twelve months to Sep 30, 2026, up 5.5% from a year earlier.
Does Cytek Biosciences pay a dividend?
No. Cytek Biosciences has not paid a cash dividend over the last twelve months.
When does Cytek Biosciences report earnings next?
Cytek Biosciences is expected to report Q4 FY2026 results on Feb 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CTKB stock performed over the past year?
Including dividends, CTKB returned +14.8% over the past year, against +12.0% for the S&P 500.
How many CTKB shares are sold short?
4M shares were sold short at the latest FINRA report, 3.53% of the float, or 3.6 days of average trading volume.
Who are Cytek Biosciences's competitors?
Companies most similar to Cytek Biosciences by business, industry and size include QTRX, PACB, HBIO, TXG, MLAB.
See a number that looks wrong?